



DERMATOLOGICAL SURGERY

TOPICAL DELIVERY OF SECRETOMES DERIVED FETAL MESENCHYMAL STEM CELL POST MICROGRAPHIC SURGERY (MOHS) IN BASAL CELL CARCINOMA : CASE REPORT SERIES

Indah Indah Julianto⁽¹⁾ - Dendy Zulfikar⁽¹⁾ - Oyong Oyong⁽²⁾ - Muhammad Eko Irawanto⁽¹⁾ - Nugrohoaji Nugrohoaji Dharmawan⁽¹⁾

Faculty Of Medicine Sebelas Maret University / Dr. Moewardi General Hospital, Dermatovenereology Departement, Surakarta, Indonesia⁽¹⁾ - Faculty Of Medicine Sebelas Maret University / Dr. Moewardi General Hospital, Pathology Anatomy Department, Surakarta, Indonesia⁽²⁾

Background: Mesenchymal stem cells (MSC) exhibit a set of pro-regenerative features, that make them an attractive candidate for modulation of immune disorders and regenerative therapy approaches. Secretome derived mesenchymal stem cell can enhances wound healing especially when MSC are applied to humans with acute wounds (after treatment for skin cancer).

Observation: Three healthy Javanese women are presented with a history of nodules on their faces since 8 until 12 years ago. In this case we use topical delivery 0.1 ml of secretomes derived fetal mesenchymal stem cell (MSCs) from warthon's jelly (WJ) in topical antitioxidant gel and we use human umbilical vein endothelial cell (HUVEC) injection 0,01 ml/0.5 cm around the lesion after micrographic surgery (MOHS) procedure.

Key message: Mesenchymal stem cells produce a variety of paracrine factors that act as immunomodulators and stimulate wound healing rapidly. The paracrine effect of MSC-conditioned medium is thought to play a role in the acceleration of wound healing. Topical delivery MSCs secretome has a promising clinical potential, proven to provide quick postoperative wound healing time to our patients, within 35 days of surgery.

